Biotech Values

[BTH]

Better than they would be for just inoperable BCC thats for sure.
The deal Curis has with Roche, imo, sucks. But, then again, is not my M.O. to invest in biotechs once the drug is approved....because, more often than not, the numbers disappoint ( see DNDN and HGSI).

I just think hitting in an indication like pancreatic will be a huge deal for visability of the pathway, and will really make INFI and CRIS much much more attractive (wall street barely looks at these companies at this point).